MONALISA® Soft Type with Lidocaine – 1 × 1ml *SALE*

MONALISA® Soft Type with Lidocaine – 1 × 1ml

Product Overview

MONALISA® Soft Type with Lidocaine is a professional cross-linked Hyaluronic Acid (HA) dermal filler developed for fine wrinkle correction, superficial facial rejuvenation and subtle soft tissue enhancement.

Manufactured by GENOSS in South Korea, MONALISA® Soft Type contains 24mg/ml cross-linked Hyaluronic Acid and 0.3% Lidocaine.

Featuring a fine 200µm particle specification, Soft Type is positioned as the smallest-particle formulation within the core MONALISA® Soft, Mild, Hard and Ultra range.

Its refined gel characteristics are designed to support precise correction, smooth tissue integration and natural-looking results in appropriately selected areas where a softer filler formulation is required.

MONALISA® Soft Type is intended primarily for fine facial wrinkles and selected superficial lines rather than significant facial volumisation or structural contouring.

The cross-linked Hyaluronic Acid gel provides an immediate smoothing and wrinkle-correcting effect following appropriate placement. Hyaluronic Acid also attracts and retains water within the tissue, helping support hydration and softness.

The formulation incorporates 0.3% Lidocaine, a local anaesthetic intended to help reduce injection-related discomfort and improve patient comfort during treatment.

Unlike skin boosters or regenerative Polynucleotide products, MONALISA® Soft Type is a cross-linked Hyaluronic Acid dermal filler designed to provide physical correction of selected fine lines and superficial wrinkles.

Pack Contents

Each pack contains:

• 1 × 1ml pre-filled syringe of MONALISA® Soft Type with Lidocaine

• Cross-linked Hyaluronic Acid: 24mg/ml

• Lidocaine: 0.3%

• Particle size: 200µm

• 2 × 30GTW needles, as specified in the supplied product information

• Sterile, sealed professional-use packaging

Total Volume: 1ml

Always check the individual product packaging, supplied needle specification, manufacturer labelling and current Instructions for Use before administration.

Product CompositionCross-Linked Hyaluronic Acid – 24mg/ml

MONALISA® Soft Type contains highly purified cross-linked Hyaluronic Acid at a concentration of 24mg/ml.

The formulation is designed to support:

• Fine wrinkle correction

• Superficial facial smoothing

• Subtle soft tissue enhancement

• Immediate physical correction

• Smooth tissue integration

• Gel stability

• Natural-looking results

Cross-linking helps improve the stability and persistence of Hyaluronic Acid within the treated tissue compared with non-cross-linked formulations.

Lidocaine – 0.3%

The formulation contains 0.3% Lidocaine, a local anaesthetic incorporated into the gel to help reduce injection-related discomfort.

Patients with known hypersensitivity to Lidocaine or other relevant product components must be appropriately assessed before treatment.

200µm HA Particle Specification

MONALISA® Soft Type features a 200µm particle specification, positioning it as the finest-particle formulation within the core MONALISA® range.

The fine gel characteristics are intended to support precise correction and smooth integration within appropriate superficial treatment planes.

MONALISA® Filler Technology

The MONALISA® dermal filler range is developed by GENOSS using Hyaluronic Acid manufacturing and cross-linking technology to create injectable HA formulations with different particle characteristics for different treatment objectives.

Highly Purified Hyaluronic Acid

GENOSS describes the MONALISA® range as being manufactured using highly purified Hyaluronic Acid for professional injectable aesthetic applications.

Cross-Linked HA Technology

The cross-linked gel matrix is designed to support gel stability and persistence within the treated tissue.

Controlled Particle Characteristics

Different formulations within the MONALISA® range incorporate different particle characteristics to accommodate varying treatment requirements.

Soft Type's 200µm particle specification positions it as the finest formulation within the core range.

Viscoelastic Gel Properties

The formulation is designed to support smooth product delivery and appropriate tissue integration following professional administration.

Ergonomic Syringe Design

The syringe is designed to support controlled product delivery and consistent injection force.

Lidocaine-Containing Formulation

The inclusion of 0.3% Lidocaine is intended to improve patient comfort during treatment.

Fine Wrinkle Correction & Superficial Rejuvenation

MONALISA® Soft Type is designed for professional treatment of selected fine facial lines and superficial wrinkles.

Its fine cross-linked HA gel is intended to support:

• Correction of fine facial wrinkles

• Improvement in selected superficial lines

• Subtle skin smoothing

• Delicate facial correction

• Natural-looking soft tissue enhancement

• Immediate physical wrinkle correction

Unlike firmer structural fillers, Soft Type is not primarily intended for substantial projection, deep volume restoration or major facial reshaping.

Its finer formulation is designed for treatment objectives requiring greater precision and more subtle correction.

Treatment suitability must always be confirmed against the manufacturer's current Instructions for Use.

Key Benefits

• Professional cross-linked Hyaluronic Acid dermal filler

• 24mg/ml HA concentration

• 0.3% Lidocaine

• Fine 200µm particle specification

• Smallest-particle formulation within the core MONALISA® range

• Designed for fine wrinkle correction

• Supports superficial facial rejuvenation

• Helps improve the appearance of selected superficial lines

• Supports subtle soft tissue enhancement

• Designed for precise product delivery

• Fine gel characteristics support smooth tissue integration

• Provides immediate correction following appropriate placement

• Cross-linked HA formulation supports gel stability

• Manufactured using highly purified Hyaluronic Acid

• Lidocaine-containing formulation helps improve treatment comfort

• Supplied with 2 × 30GTW needles, subject to pack verification

• Supplied in a 1ml pre-filled syringe

• Intended for appropriately qualified professional use

Common Treatment Areas

MONALISA® Soft Type may be considered for facial areas requiring fine, superficial correction.

Potential applications described in the supplied product information include:

• Fine facial wrinkles

• Crow's feet

• Selected periorbital fine lines

• Fine forehead lines

• Superficial perioral lines

• Selected delicate facial areas

• Other superficial lines and wrinkles

The supplied product information also references lower-eyelid and tear-trough applications.

The periorbital and tear-trough regions are anatomically complex, higher-risk treatment areas. Their inclusion in product literature should not be interpreted as confirmation that every periocular application is authorised or appropriate.

Any proposed treatment in these regions requires explicit confirmation of the manufacturer's current indications, specialist training, careful patient selection and appropriate complication-management arrangements.

Treatment suitability must always be determined following assessment of facial anatomy, vascular structures, tissue characteristics, skin quality and individual treatment objectives.

MONALISA® Soft Type vs Mild Type vs Hard Type

The MONALISA® range includes formulations with different gel and particle characteristics to accommodate different treatment objectives.

MONALISA® Soft Type

Particle Specification: 200µm

Positioned primarily for:

• Fine wrinkle correction

• Superficial facial lines

• Subtle soft tissue enhancement

• Delicate correction where authorised

• Natural-looking superficial smoothing

MONALISA® Mild Type

Particle Specification: 400µm

Positioned primarily for:

• Moderate wrinkle correction

• Lip contour and volume

• Natural facial volume enhancement

• Selected perioral concerns

• Moderate soft tissue augmentation

MONALISA® Hard Type

Positioned as a firmer structural formulation for:

• Deeper wrinkle and fold correction

• Facial volume restoration

• Greater tissue support

• Chin contour enhancement

• Jawline definition

• Selected areas requiring greater projection

Product selection should always be based on the manufacturer's current indications, gel characteristics, patient anatomy and professional assessment rather than HA concentration or particle size alone.

Professional Treatment Considerations

MONALISA® Soft Type is intended for administration by appropriately qualified and trained professionals with suitable competence in dermal filler treatments and facial anatomy.

Treatment planning should include:

• Comprehensive patient consultation

• Review of medical history

• Assessment of facial anatomy

• Evaluation of skin and soft tissue characteristics

• Assessment of the proposed treatment area

• Review of previous aesthetic treatments

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Published product specifications position Soft Type for superficial dermal treatment.

The precise treatment depth and technique must always be determined according to the specific anatomical area, the manufacturer's current Instructions for Use and appropriate professional training.

Needle or cannula selection, product volume and placement must be individually determined by the treating practitioner.

Particular care is required when assessing delicate or periocular treatment areas because of their vascular anatomy and the potential for oedema, contour irregularity and serious filler-related complications.

MONALISA® Soft Type should not be administered using a generic injection protocol without appropriate consideration of individual facial and vascular anatomy.

Treatment Review & Maintenance

The supplied product information describes an initial treatment followed by professional reassessment.

A clinical review may commonly be considered approximately 2–4 weeks following treatment, according to practitioner protocol and individual patient requirements.

Additional correction should only be considered following appropriate assessment.

Maintenance requirements will depend on:

• Treatment area

• Product persistence

• Individual anatomy

• Patient metabolism

• Facial movement

• Tissue characteristics

• Previous treatment response

• Individual aesthetic objectives

Treatment intervals and product volumes must always be determined through professional assessment and the manufacturer's current guidance.

Results & Longevity

MONALISA® Soft Type is designed to provide an immediate smoothing and wrinkle-correcting effect following appropriate administration.

Potential treatment outcomes may include:

• Improvement in selected fine facial lines

• Reduction in the appearance of superficial wrinkles

• Smoother-looking treated areas

• Subtle soft tissue enhancement

• Natural-looking superficial correction

Initial swelling, redness or localised treatment response may temporarily influence the appearance of the treated area.

As treatment-related swelling subsides, the final result may become more apparent.

The duration of results varies according to:

• Treatment area

• Product volume

• Administration technique

• Patient metabolism

• Facial movement

• Patient age

• Lifestyle factors

• Tissue characteristics

• Individual biological response

No fixed duration of results is guaranteed.

Maintenance treatment may be considered following professional reassessment where appropriate.

Storage & Handling

Store MONALISA® Soft Type according to the manufacturer's current storage recommendations.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow the manufacturer's specified storage conditions.

• Protect from inappropriate environmental exposure.

• Inspect the syringe and packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Do not use if the sterile packaging is damaged.

• Do not use if the syringe appears compromised.

• Do not use after the stated expiry date.

The product should be handled using appropriate aseptic procedures.

Each syringe is intended for single use only.

Important Information

MONALISA® Soft Type with Lidocaine is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Professional knowledge of the following is essential:

• Facial anatomy

• Facial vascular anatomy

• Dermal filler administration

• Appropriate treatment planes

• Patient selection

• Aseptic technique

• Complication prevention

• Vascular compromise recognition

• Emergency management

• Dermal filler complication management

Patient Assessment & Contraindications

Treatment should only proceed following a full patient consultation, medical assessment and appropriate informed consent.

Treatment suitability must be assessed according to the manufacturer's current Instructions for Use.

Factors requiring particular consideration include:

• Active infection or inflammation within the proposed treatment area

• Known hypersensitivity to Hyaluronic Acid

• Known hypersensitivity to Lidocaine or other product components

• Pregnancy or breastfeeding

• Relevant uncontrolled medical conditions

• Previous filler treatments within the proposed treatment area

• Other contraindications identified during professional assessment

This list is not exhaustive and does not replace the manufacturer's official contraindications.

Potential Side Effects

Temporary treatment-related effects may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Localised discomfort

• Temporary firmness

• Injection-site sensitivity

• Localised irregularity

Serious Complications

More serious complications associated with injectable dermal filler procedures may include:

• Infection

• Vascular compromise or occlusion

• Tissue ischaemia or necrosis

• Delayed inflammatory reactions

• Nodules

• Product migration

• Persistent contour irregularities

• Visual impairment or blindness associated with vascular complications

Periorbital procedures may also present particular risks of persistent oedema, visible product irregularity and other complications.

Practitioners must be appropriately trained in the prevention, recognition and management of filler-related complications, including emergency escalation where required.

Patients should receive appropriate written aftercare information and clear instructions regarding symptoms requiring urgent medical attention.

Always consult the manufacturer's current Instructions for Use for complete indications, contraindications, precautions, warnings, administration guidance and potential adverse events.

Do not use if:

• The sterile packaging is damaged or compromised

• The syringe appears damaged

• The product has passed its expiry date

• Product integrity is in doubt

• Product authenticity cannot be verified

For appropriately qualified professional use only.